Preliminary Dose Escalation Results from a Phase I/II, FIH Study of MGC018 in Patients with Advanced Solid Tumors

Time: 12:30 pm
day: day 1 track 3 am


• Examine B7H3 as a target for
an ADC with a duocarmycin
• Presenting a safety overview
from Phase 1 Dose Escalation
• Analyze efficacy from
preliminary evidence of a Phase
1 enrollment with focus on
prostate cancer